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Background: Most childhood cancer survivors will develop ionizing radiation treatment-related health conditions
that, in many instances, resemble age-associated pathologies. Treatment-induced premature senescence could be
an underlying mechanism.
Findings: Here we wanted to know whether the expression of p16INK4a, a senescence/aging biomarker, is increased
in skin biopsies of acute lymphoblastic leukemia survivors (ALL), previously exposed to chemotherapy and radiation
therapy. Several years post-treatments, we found p16INK4a mRNA levels are 5.8 times higher in scalp skin biopsies
(targeted by cranial irradiation therapy) compared to buttocks skin biopsies (n = 10, p = 0.01).
Conclusions: These results demonstrate for the first time that premature senescence is induced in pediatric cancer
survivors and that p16INK4a expression could be used as a potential biomarker in this population.
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Introduction
The majority of children treated for cancer will eventually
develop at least one chronic medical condition related to
their previous exposure to chemotherapy and/or radiation
therapy [1,2]. Identifying a biomarker indicative of global
damage level would be useful in predicting individual sen-
sitivity to anti-cancer treatment long-term side effects.
Cellular senescence was first observed in vitro and for
a long time, was believed exclusively dependent on telo-
meres length. Since then, it has been shown that cellular
senescence can be triggered prematurely by various stim-
uli such as DNA damage, oncogenic stress and oxidative
stress [3]. More specifically, ionizing radiation (IR) and
chemotherapy can induce p16INK4a, a senescence marker,
in murine models [4,5]. We also showed that a DNA dam-
age response (a hallmark of senescence) is observed up to* Correspondence: christian.beausejour@recherche-ste-justine.qc.ca
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reproduction in any medium, provided the orone year post-exposure to IR in the skin of cancer patients
[5]. Induction of senescence has been shown to be trig-
gered as a tumor preventive mechanism in humans [6]
and, more recently, as a program limiting fibrosis in mice
stellate liver cells [7].
p16INK4a is a tumor suppressor gene and arguably the
best biomarker for cellular senescence [8]. Briefly stated,
it induces irreversible cell cycle arrest by preventing Rb
phosphorylation [9,10]. Its expression correlates with
aging in various mice tissues and human lymphocytes
[11-13]. Expression of p16INK4a was also shown to limit
progenitor cells renewal with age in neural [14], bone
marrow [15] and islet mouse tissues [16]. Moreover,
clearance of p16INK4a positive cells delays some aging-
associated disorders [17]. Given these evidences, it is
reasonable to hypothesize that an increase in p16INK4a
expression following exposure to IR and/or chemotherapy
may contribute to treatment-related late effects observed
in cancer survivors. This project aimed at verifying
whether a higher expression of p16INK4a could be found in
patients’ skin areas directly targeted by radiation therapy.l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The project was approved by the Institutional Review
Board and informed consent was obtained from each
participant. Patients were recruited among the long-term
follow-up clinic. All patients were treated according to
Dana Farber Cancer Institute ALL Consortium treatment
protocols (91–01, 95–01 or 00–01) [18-20]. Eligibility
criteria were: having received an ALL diagnosis before
age 18, having no evidence of active disease, having re-
ceived cranial irradiation as part of the ALL treatment,
having no history of other previous disease requiring
chemotherapy and/or radiation therapy. The first 10
families recruited were enrolled in this study (participa-
tion rate of approximately 30%).
Skin biopsies
This procedure was performed by a dermatologist and
consisted of three millimiters diameter biopsies contain-
ing all skin layers. For each participant, 2 biopsies were
performed: one in the scalp region targeted by cranial
radiation therapy (‘scalp’; n = 10), and one from a non-
irradiated (n = 8) or irradiation-exposed in the context
of total body irradiation (TBI) (n = 2) (‘buttocks’). When-
ever possible, a skin biopsy from the buttocks of siblings
was also obtained.
p16INK4a measurements
Biopsies were kept in an RNAlater solution (QIAGEN
Cat#76160) at a temperature of 4°C. RNA extraction was
done by using the RNeasy Lipid Tissue Mini kit (QIAGEN
Cat#74804). Reverse transcription (RT) reactions were
done by using the QuantiTect Reverse Transcription kit
(QIAGEN). Expression of p16INK4a mRNA was quantified
by qPCR (standard curve method) using at least two
independent RT reactions for each biopsy and the
SensiMix TM SYBR Low ROX Kit (BIOLINE). The follow-
ing primers were used: (forward) CCAACGCACCGAA-
TAGTTACG, (reverse) GCGCTGCCCATCATCATG. 18 s
expression was also measured, as a mean to normalize
p16INK4a levels. 18 s primers were (forward) TCAACTTTCTable 1 Patients’ characteristics
Variables
1 2 3 4
Age at diagnosis 5 7 3 5
Age biopsy 17 23 17 20
Gender1 F M M M
Years since diagnosis 12 16 14 15
Treatment protocol DFCI 95-01 91-01 95-01 95-0
stem cell transplantation no no no no
Cranial radiation dose (18 Gy) yes yes yes yes
1All patients were caucasian. F = female, M =male.GATGGTAGTCGCCGT, (reverse) TCCTTGGATGTGGT
AGCCGTTTCT.
Statistical analysis
Four measurements of p16INK4a and 18 s mRNA were
independently measured for each biopsy. The average of
these measurements was used for statistical analyses. All
statistical analyses were performed using SPSS 17.0.
Results
Patients’ characteristics are shown in Table 1. A paired
t-test revealed that p16INK4a mRNA expression was 5.8
times higher in the scalp biopsies (‘irradiated zone’) com-
pared to the buttock biopsies (‘non-irradiated zone’)
(Figure 1A; p = 0.01). No significant differences in p16INK4a
expression levels were observed between buttock biopsies
collected from patients compared to those collected from
siblings (data not shown). This suggests that neither
exposure to chemotherapy nor lower level of irradi-
ation (2 patients had received total body irradiation in
addition to cranial irradiation) leads to p16INK4a ex-
pression in human skin. Of note, there is an important
heterogeneity in the p16INK4a fold increase expression
in scalp biopsies (Figure 1B). Surprisingly, and in opposite
to what we observed previously in irradiated mouse
tissues [5], p21 and p14ARF (a tumor suppressor gene
expressed from the same locus as p16INK4a) were also
generally increased in the scalp biopsies, although not
reaching statistical significance (Additional file 1: Figure S1);
p = 0.11 and p = 0.07 respectively. Yet, IL-6 mRNA levels
(a senescence-associated secretory phenotype marker)
[21] was not increased in all but one scalp biopsy (data
not shown). Similarly, and in contrast to what was ob-
served in benign prostatic hyperplasia [22], no increase in
PML or PML-IV were observed.
Discussion
The senescence/aging biomarker p16INK4a is more
expressed in irradiated skin portions of ALL survivors
compared to non-irradiated or scarcely irradiatedPatients
5 6 7 8 9 10
10 9 3 1 4 3
24 25 19 13 14 13
M M F M M M
14 16 14 6 10 11
1 91-01 91-01 91-01 95-01 00-01 95-01
no no yes yes no no
yes yes yes yes yes yes
Figure 1 p16INK4A mRNA levels in irradiated compared to
non-irradiated tissues. p16INK4A mRNA was quantified by qPCR
and was normalized using 18 s mRNA expression level. qPCR was run
four times independently for each biopsy. Error bars represent +/− 1 S.D.
(A) The average expression level for biopsies from patients’ scalp was
found to be significantly higher than the average expression level for
biopsies from the buttocks (n = 10 patients, paired t-test). (B) Individual
participants’ p16INK4A mRNA expression levels. # indicates patients who
received 12 Gy TBI in addition to cranial irradiation. Skin biopsy
from siblings was not available for patients 9 and 10.
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induced senescent cells in skin of these patients do not get
cleared up, even after an average of 12 years post-
diagnosis. We thus propose that p16INK4a could be further
studied as a potential biomarker for long-term sequelae in
childhood ALL survivors and suggest that premature sen-
escence could be considered as a mechanism behind side-
effects in this population. Our finding that p14ARF ap-
pears coregulated with p16INK4a was unexpected based
on our observation that it was not in irradiated mice tis-
sues [5]. One explanation for this discrepancy, aside
from the species difference, is the time post exposure
which was much longer in patients. Noteworthy, the ex-
pression of both genes was shown to be coregulated dur-
ing aging in rodents tissues [12], but not in human
lymphocytes [13].
The small number of participants is a limitation of
this pilot study. Despite the pain associated to the
biopsy being estimated similar to that of taking ablood sample by participants, this method led to a signifi-
cant number of potential participants to decline our invi-
tation to the study. To ease patients’ recruitment, we
measured p16INK4a levels in blood lymphocytes, aiming
for a sampling method more acceptable to participants.
Unfortunately, no average difference in p16INK4a levels
was detected between a group of various childhood
cancer survivors who had received radiotherapy as part
of their treatment and a group of healthy participants
(n = 11, data not shown). While Liu et al. have detected
some differences in p16INK4a levels with age using blood
lymphocytes [23], our incapacity to do so could be ex-
plained by at least three possibilities: first, only a frac-
tion of the progenitor lymphocytes are exposed during
irradiation, given that the radiotherapy-targeted zone
is restricted to the head. Second, the half-life of T
lymphocytes is difficult to tell and it is very likely that
a majority of those who were irradiated were cleared
out by the time the blood samples were taken. Third,
a lack of statistical power cannot be excluded. Another
limitation is associated to the location of the biopsy.
The upper occipital area was an indicated biopsy site
given it is irradiated in childhood ALL patients as part
of CNS prophylaxis. Buttocks were chosen as the in-
ternal control site for ethical reason, as it minimizes
the visibility of the second scar. It is known that UV
radiations can be genotoxic [24] and as such, it is possible
that for some patients, extensive head sun exposure may
have played a partial role in the elevated p16INK4a expres-
sion observed compared to the biopsies from the buttock.
Scalp biopsies were however taken from the upper occipi-
tal region, an area that is not expected to receive sun
exposure unless it has been previously fully shaved, a
haircut that none of the patient was bearing at the time
biopsies were performed.
Using p16INK4a expression level as a biomarker for
long-term health problems in childhood cancer patients
could be useful in the screening for patients at risk and
in the development of optimized treatments. The het-
erogeneity in the sensitivity to treatment toxicity would
be coherent with the heterogeneity in p16IKN4A mRNA
expression fold increase we observed (Figure 1B). Fur-
thermore, since p16INK4a is likely to be not only a bio-
marker, but also a mediator of senescence/aging, it may
itself represent an interesting therapeutic avenue in the
prevention of long-term health problems. Removal of
senescent cells induced by radiotherapy in ALL survivors
may be considered in the future to prevent long-term
side-effects.
There is clearly a need for additional senescence studies
using humans beings rather than murine models given the
physiological differences reviewed in [25]. Comprehen-
sive studies investigating the associations between sen-
escence biomarkers, histological changes and organs
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behind the observed heterogeneity in long-term side-
effects occurrence must also be further investigated:
genetic studies, including polymorphisms studies, should
provide important clues.
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